Table 1 Clinical characteristics of the study groups (n = 234)
|  | Overall | Stable CAD (n = 143) | Non-CAD (n = 91) | p value |
|---|---|---|---|---|
Age, years | 65.9 ± 10.5 | 67.9 ± 10.3 | 62.8 ± 10.2 | < 0.001 |
Gender, male, n (%) | 153 (65.4) | 104 (72.7) | 49 (53.8) | 0.003 |
BMI (kg/m2) | 24.1 ± 2.4 | 24.2 ± 2.5 | 23.9 ± 2.4 | 0.450 |
Smoking, n (%) | 102 (43.6) | 68 (47.6) | 34 (37.4) | 0.125 |
SBP (mmHg) | 136 ± 15 | 135 ± 15 | 137 ± 14 | 0.340 |
DBP (mmHg) | 82 ± 11 | 81 ± 10 | 83 ± 12 | 0.161 |
Triglycerides (mmol/L) | 1.62 (1.23–2.20) | 1.65 (1.26–2.20) | 1.57 (1.09–2.20) | 0.266 |
TC (mmol/L) | 4.54 ± 1.03 | 4.66 ± 1.07 | 4.36 ± 0.94 | 0.031 |
LDL cholesterol (mmol/L) | 2.60 ± 0.83 | 2.67 ± 0.91 | 2.49 ± 0.68 | 0.102 |
HDL cholesterol (mmol/L) | 1.18 ± 0.28 | 1.15 ± 0.29 | 1.21 ± 0.26 | 0.082 |
Platelet count(× 104/μl) | 185 (166–217) | 183 (154–216) | 196 (167–230) | 0.099 |
Creatinine (μmol/L) | 76 (65–87) | 76 (66–89) | 73 (62–81) | 0.067 |
Glucose (mmol/L) | 5.5 (4.9–6.9) | 5.7 (5.0–7.2) | 5.4 (4.8–6.7) | 0.162 |
Diabetes mellitus, n (%) | 79 (33.8) | 58 (59.4) | 21 (23.1) | 0.006 |
Hypertension, n (%) | 156 (66.7) | 107 (74.8) | 49 (53.8) | 0.001 |
Medication use, n (%) | ||||
 Aspirin | 68 (29.1) | 44 (30.8) | 24 (26.4) | 0.566 |
 Beta-blocker | 68 (29.1) | 41 (28.7) | 27 (29.7) | 0.987 |
 Statin | 55 (23.5) | 34 (23.8) | 21 (23.1) | 0.902 |
 ACEI/ARB | 95 (40.6) | 59 (41.3) | 36 (39.6) | 0.903 |
 CCB | 104 (44.4) | 64 (44.8) | 40 (44.0) | 0.905 |
CRP (mg/L) | 1.17 (0.67–2.20) | 1.23 (0.69–2.20) | 0.93 (0.61–2.21) | 0.079 |
vWF (IU/dl) | 102 ± 26 | 111 ± 27 | 89 ± 18 | < 0.001 |
BDNF (pg/ml) | 1187 (784–1543) | 937 (679–1263) | 1361 (884–1846) | < 0.001 |